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Urban yellow fever is transmitted from person to person
through the bite of an infected Aedes aegypti mosquito. In
recent years, reinfestations of Ae. aegypti have occurred in
countries throughout the world, contributing to the threat
of epidemic yellow fever reemergence in new locations and
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Summary
This report updates CDC’s recommendations for using yellow fever vaccine (CDC. Yellow Fever Vaccine: Recommendations
of the Advisory Committee on Immunizations Practices: MMWR 1990;39[No. RR-6]1–6). The 2002 recommendations
include new or updated information regarding 1) reports of yellow fever vaccine-associated viscerotropic disease (previously re-
ported as febrile multiple organ system failure); 2) use of yellow fever vaccine for pregnant women and persons infected with
human immunodeficiency virus (HIV); and 3) concurrent use of yellow fever vaccine with other vaccines. A link to this report and
other information related to yellow fever can be accessed at the website for Travelers’ Health, Division of Global Migration and
Quarantine, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/travel/index.htm, and through the website for
the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/
dvbid/yellowfever/index.htm.
Introduction
Yellow fever occurs only in Africa and South America. The
World Health Organization (WHO) estimates that a total of
200,000 cases of yellow fever occur each year (1). The clinical
spectrum of yellow fever ranges from subclinical infection to
overwhelming pansystemic disease (2). Yellow fever has an
abrupt onset after an incubation period of 3–6 days, and usu-
ally includes fever, prostration, headache, photophobia, lum-
bosacral pain, extremity pain (including the knee joints),
epigastric pain, anorexia, and vomiting. The illness might
progress to liver and renal failure, and hemorrhagic symptoms
and signs caused by thrombocytopenia and abnormal clotting
and coagulation can occur. The fatality rate of severe yellow
fever is approximately 20%.
Definitive diagnosis is made by viral culture of blood or
tissue specimens or by identification of yellow fever virus
antigen or nucleic acid in tissues (including liver) using
immunohistochemistry (IHC), enzyme-linked immuno-
sorbent assay (ELISA) antigen capture, or polymerase chain
reaction tests (3). Although antibodies are not always present
during the first week of illness, detection of yellow fever-
specific immunoglobulin M (IgM) antibody by capture ELISA
with confirmation of >4-fold rise in neutralizing antibody
titers between acute- and convalescent-phase serum samples is
also diagnostic.
Treatment for yellow fever consists of providing general sup-
portive care and varies, depending on which organ systems are
involved. No effective specific antiviral therapy for yellow
fever has been identified.
Two forms of yellow fever, urban and jungle, are epidemio-
logically distinguishable. Clinically and etiologically they are
identical (4,5). Urban yellow fever is an epidemic viral disease
of humans transmitted from infected to susceptible persons
by Aedes aegypti mosquitoes, which breed in domestic and
peridomestic containers (e.g., water jars, barrels, drums, tires,
or tin cans) and thus in close association with humans. In
areas where Ae. aegypti has been eliminated or suppressed,
urban yellow fever has disappeared. In the mid-1900s, eradi-
cation of Ae. aegypti in multiple countries, notably Panama,
Brazil, Ecuador, Peru, Bolivia, Paraguay, Uruguay, and Argen-
tina, led to the disappearance of urban yellow fever. The last
documented Ae. aegypti-borne yellow fever epidemic in the
western hemisphere occurred in Trinidad in 1954. However,
in recent years, reinfestation of countries that had previously
eradicated Ae. aegypti has occurred (5). Ae. aegypti mosquitoes
are strongly suspected as having played a role in transmission
in outbreaks occurring in Bolivia in 1989, 1990, and 1998
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(6,7). Other countries remain infested, including areas of Ven-
ezuela and the Guianas, which include enzootic areas for jungle
yellow fever. In Africa, yellow fever epidemics caused by trans-
mission by Ae. aegypti continue to occur and involve human
populations both in towns and in rural villages (8,9).
Jungle yellow fever is primarily an enzootic viral disease trans-
mitted among nonhuman primate hosts by different mosquito
vectors, but endemic and epidemic jungle yellow fever can
occur. It is observed only in forest-savannah zones of tropical
Africa and in forested areas of South America but, in the past,
occasionally extended into parts of Central America; it is
enzootic in the jungles on the island of Trinidad. In South
America, approximately 500 human cases are reported annu-
ally, primarily among men with occupational exposures in for-
ested areas; however, the disease is believed to be substantially
underreported (10). In Africa, epidemics involving tree-
hole–breeding mosquito vectors affect thousands of persons
at intermittent intervals, but only a limited number of cases
are officially reported. Sometimes the disease is not detected
in an area for years but then will reappear. Delineation of
affected areas depends on surveillance for animal reservoirs
and vectors, accurate diagnosis, and prompt reporting of all
human cases. The jungle yellow fever cycle might be active
but unrecognized in forested areas of countries within the yel-
low fever-endemic zone (Figure).
Urban yellow fever can be prevented by vaccinating human
populations at risk for infection or by suppressing popula-
tions of Ae. aegypti mosquitoes so that they no longer per-
petuate infection. Jungle yellow fever can most effectively be
prevented by vaccination of human populations at risk for
exposure.
Yellow Fever Vaccine
Yellow fever vaccine is a live, attenuated virus preparation
made from the 17D yellow fever virus strain (11). Histori-
cally, the 17D vaccine has been considered to be one of the
safest and most effective live virus vaccines ever developed
(2,12). The virus is grown in chick embryos inoculated with a
seed virus of a fixed passage level. The 17D yellow fever vac-
cine virus family is the foundation for both the 17D-204 lin-
eage and 17DD lineage. Vaccine type 17D-204 is used in both
the United States and Australia, whereas vaccine type 17DD
is used in Brazil. The two vaccine types share 99.9% sequence
homology (13).
The 17D-204 strain YF-VAX® (manufactured by Aventis,
Swiftwater, Pennsylvania) vaccine is a freeze-dried superna-
tant of centrifuged embryo homogenate, packaged in 1-dose
and 5-dose vials for domestic use. The vaccine should be stored
at temperatures of 2ºC–8ºC (35ºF–46ºF) until it is reconsti-
tuted by the addition of diluent (sterile, physiologic saline)
supplied by the manufacturer. Multidose vials of reconstituted
vaccine should be held at 2ºC–8ºC (35ºF–46ºF); unused vac-
cine should be discarded within 1 hour after reconstitution.
Vaccine Use
Persons Living or Traveling in Endemic Areas
Persons aged >9 months who are traveling to or living in
areas of South America and Africa where yellow fever infec-
tion is officially reported should be vaccinated. These areas
are listed in the “Bi-Weekly Summary of Countries with
Areas Infected with Quarantinable Diseases,” available at state
and local health departments. Information concerning known
or probable infected areas is also available from WHO (http://
www.who.int), the Pan American Health Organization, the
Division of Vector-Borne Infectious Diseases (telephone: 970-
221-6400) or the Division of Global Migration and Quaran-
tine (telephone: 404-498-1600) at CDC, or at http://
www.cdc.gov/travel.
Vaccination is also recommended for travel to countries that
do not officially report the disease but that lie in the yellow
fever-endemic zone (see shaded areas in the figure). In recent
years, fatal cases of yellow fever have occurred among unvac-
cinated tourists from the United States and Europe who vis-
ited rural areas within the yellow fever-endemic zone (3,14–18).
Because of incomplete surveillance, the actual areas of yellow
fever virus activity might exceed the infected zones officially re-
ported by individual ministries of health.
The manufacturer and the Food and Drug Administration
(FDA) recommend that vaccination of infants aged <9 months
be avoided because of the risk for encephalitis, and that travel
of such persons to countries in yellow fever-endemic zones or
to countries experiencing an epidemic be postponed or avoided,
whenever possible. Using yellow fever vaccine among infants
aged <9 months has not been formally evaluated. Since 1945,
among the reported cases of vaccine-associated encephalitis,
only two cases have been reported of children aged 6 and 7
months developing encephalitis after yellow fever vaccination.
In comparison, 14 such cases have occurred among children
aged <4 months and seven cases among persons aged >3 years
(including two fatal cases in persons aged 3 and 53 years).
Because recent experience in use of the vaccine among chil-
dren aged <6 months is limited and because age-specific vac-
cine administration records are not available, calculation of
age-specific rates of yellow fever vaccine-associated encephali-
tis is impossible. In unusual circumstances, physicians con-
sidering vaccinating infants aged <9 months or pregnant
women should contact the Division of Vector-Borne
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Infectious Diseases (telephone: 970-221-6400) or the Divi-
sion of Global Migration and Quarantine (telephone: 404-
498-1600) at CDC for advice (see Precautions and
Contraindications).
Despite the lack of such information, ACIP and WHO rec-
ognize that situations occur in which vaccination of an infant
aged <9 months might be considered. One such situation is
the unavoidable exposure of children aged 6–8 months to an
environment where an increased likelihood of becoming
infected with the yellow fever virus exists (e.g., a setting of
endemic or epidemic yellow fever) (1). Because of the risk for
encephalitis, in no instance should infants aged <6 months
receive yellow fever vaccine.
Because the seroconversion rate after vaccination of preg-
nant women might be markedly reduced compared with that
of other healthy women, serologic tests to determine if a
specific yellow fever immune response exists should be
considered. To discuss the need for serologic testing, the
appropriate state health department or the Division of
Vector-Borne Infectious Diseases (telephone: 970-221-6400)
or the Division of Global Migration and Quarantine
(telephone: 404-498-1600) at CDC should be contacted (see
Precautions and Contraindications).
Laboratory Personnel
Laboratory personnel who might be exposed to virulent yel-
low fever virus or to concentrated preparations of the 17D



















































































FIGURE 1. Yellow Fever endemic zones
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Requirements for Vaccination Before
International Travel
For purposes of international travel, yellow fever vaccines
produced by different manufacturers worldwide must be
approved by WHO and administered at an approved yellow
fever vaccination center. In addition to CDC’s Division of
Global Migration and Quarantine, state and territorial health
departments have the authority to designate nonfederal vacci-
nation centers; these centers can be identified by contacting
state or local health departments. Vaccinees should receive an
International Certificate of Vaccination that has been com-
pleted, signed, and validated with the center’s stamp when the
vaccine is administered. Vaccination for international travel
might be required under circumstances other than those speci-
fied in this report. Certain countries in Africa require evidence
of vaccination from all entering travelers. Other countries
might waive the requirements for travelers coming from areas
where no evidence exists of substantial risk for yellow fever
and who are staying <2 weeks. Because requirements might
change, all travelers should seek up-to-date information from
health departments, CDC, and WHO. Travel agencies, inter-
national airlines, or shipping lines also should have up-to-date
information. Certain countries require persons, even if only
in transit, to have valid International Certificates of Vaccina-
tion if they have been in countries either known or thought to
have yellow fever virus. Such requirements might be enforced
strictly, including for persons traveling from Africa or South
America to Asia. Travelers should consult CDC’s travel infor-
mation website at http://www.cdc.gov/travel (19) to determine
requirements and regulations for vaccination.
Primary Vaccination
For persons of all ages for whom vaccination is indicated, a
single subcutaneous injection of 0.5 mL of reconstituted vac-
cine is used.
Booster Doses
The International Health Regulations require revaccination
at intervals of 10 years. Revaccination can boost antibody
titer; however, evidence from multiple studies (20–23) dem-
onstrates that yellow fever vaccine immunity persists for 30–
35 years and probably for life.
Safety
General Events
Reactions to 17D yellow fever vaccine are typically mild.
After vaccination, vaccinees have reported mild headaches,
myalgia, low-grade fevers, or other minor symptoms for 5–10
days. In clinical trials, where symptoms are actively elicited,
incidence of mild adverse events has been <25% (24,25).
Approximately 1% of vaccinees curtail regular activities.
Immediate hypersensitivity reactions, characterized by rash,
urticaria, or asthma, are uncommon (i.e., an estimated inci-
dence of 1/130,000–250,000) and occur principally among
persons with histories of allergies to egg or other substances
(26). Gelatin is used as a stabilizer in different vaccines,
including yellow fever vaccine. Gelatin has been implicated as
a cause of allergic reaction related to other vaccines and, there-
fore, might also do the same regarding yellow fever vaccine
(27–29). Vaccine strain viremia after primary vaccination with
yellow fever vaccine frequently occurs among healthy persons,
but is usually waning or absent after the first week (2,30).
Yellow Fever Vaccine-Associated
Neurotropic Disease
Historically, yellow fever vaccine-associated neurotropic dis-
ease (formerly known as postvaccinal encephalitis) among
children has been the most common serious adverse event
associated with yellow fever vaccines. Worldwide, only 23 cases
of encephalitis temporally associated with or confirmed to be
caused by 17D vaccine have been reported in the scientific
literature since the introduction of the 17D seed lot system in
1945 (2,31–33); of these, 16 have occurred among children
aged <9 months. The other seven cases occurred among per-
sons aged 3–76 years. Only three of these cases of encephalitis
were associated with vaccinations in the United States; one
occurred in 1959 (in a person aged 10 weeks); the second in
1965 (in a person aged 3 years); and one in 1998 (in a person
aged 76 years). One of the three cases was fatal, and 17D virus
was isolated from the brain of this patient (33). Since 1965,
only one case of yellow fever vaccine-associated encephalitis
in the United States has been reported in the scientific litera-
ture. The case occurred in a male aged 76 years who suffered
both yellow fever vaccine-associated neurotropic disease and
yellow fever vaccine-associated viscerotropic disease (31). The
most recent case of possible yellow fever vaccine-associated
neurotropic disease was reported in 2002 from Thailand and
involved a man aged 53 years who had unrecognized human
immunodeficiency virus (HIV) infection (32). Recently, four
reports have been made to the Vaccine Adverse Event Report-
ing System (VAERS) of encephalitis among adult recipients
of yellow fever vaccine (persons aged 16, 36, 41, and 71 years)
with onset of illness 4–23 days after vaccination. The occur-
rence of vaccine-associated neurotropic disease does not
appear to be confined to infants but does appear to be limited.
The risk for vaccine-associated neurotropic disease has been
estimated as <1/8,000,000 persons (2).
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Yellow Fever Vaccine-Associated
Viscerotropic Disease
Recently, a new serious adverse reaction syndrome has been
described among recipients of different yellow fever vaccines.
This syndrome was previously reported as febrile multiple
organ system failure, and is now called yellow fever vaccine-
associated viscerotropic disease. In July 2001, the first seven
case reports of this syndrome appeared in the scientific litera-
ture. These cases occurred during 1996–2001 and described
patients with severe multiple organ system failure; 6 of the 7
patients died (31,34–36). Subsequently, retrospective and pro-
spective case finding has identified three additional suspected
cases (37–39). These additional cases demonstrate that this
serious adverse reaction probably occurs as a clinical spectrum
of disease severity, from moderate illness with focal organ dys-
function to severe disease with overt multiple organ system
failure and death. These 10 cases demonstrate the viscerotro-
pic potential of 17D vaccine virus among certain persons.
A phase III nonplacebo controlled clinical trial was recently
completed that compared safety and reactogenicity among
1,440 healthy volunteers randomized to receive either one of
two 17D-204 vaccines, ARILVAX™ (manufactured by Evans
Vaccines Speke, Liverpool, United Kingdom) or YF-VAX®
(Aventis Pasteur Inc., Swiftwater, Pennsylvania) (24). Adverse
events were actively monitored for 30 days. Although no pla-
cebo group was included, which limits the interpretation of
results, 3%–4% of vaccine recipients in both arms of the study
experienced mild elevation of hepatic transaminases within
the first 10 days after vaccination; all enzyme elevations
returned to normal by day 30 postvaccination. Finally, mount-
ing evidence exists that persons are most at risk for yellow
fever vaccine-associated viscerotropic disease after their first
vaccination. All cases reported thus far have occurred among
such persons. In addition, clinical studies have demonstrated
that mild adverse events after yellow fever vaccination are less
common among previously immunized persons (24) and that
vaccine viremia is not detectable among those receiving booster
doses (30).
Vaccine-Associated Viscerotropic Disease Among U.S.
Citizens. During 1996–1998, four U.S. citizens (aged 63, 67,
76, and 79 years) became ill 2–5 days after receiving YF-VAX
(17D-204 vaccine) (31). All four persons required intensive
care after they experienced fever, hypotension, respiratory fail-
ure, elevated hepatocellular enzymes, hyperbilirubinemia, lym-
phocytopenia, and thrombocytopenia; three of the four also
experienced renal failure, which required hemodialysis. Three
of the four died.
Blood was available for viral isolation from two of the four
patients. Vaccine-type yellow fever virus was isolated from the
blood of both of these patients 7–8 days after vaccination.
Cerebrospinal fluid was also available from one of the two
patients. Virus was isolated from this specimen, which was
obtained when the patient experienced encephalitis (31). Mini-
mal periportal inflammation without hepatocellular necrosis
was observed in the liver specimen from the only U.S. patient
who underwent a liver biopsy 28 days after illness onset; IHC
revealed limited numbers of Kupffer cells containing yellow
fever virus antigen.
In the United States, safety-monitoring data were available
for an estimated 1.55 million vaccine doses of YF-VAX (17D-
204) vaccine distributed to civilian vaccination centers in the
United States during 1990–1998 (40). During this period,
four cases of yellow fever vaccine-associated viscerotropic dis-
ease were reported to VAERS, providing an estimated reported
incidence of 2.5/1,000,000 (or 1/400,000) doses distributed.
YF-VAX was also administered to approximately 9 million
military personnel during the same period of observation
(1990–1998). This estimated incidence based on VAERS
might be low because of limitations (e.g., underreporting of
cases and imprecise information regarding the number of doses
actually administered, including to nonimmune primary
vaccinees who appear to be the major, if not only, risk group) (41).
Vaccine-Associated Viscerotropic Disease Among Persons
Outside the United States. In addition to the cases reported
in the United States, in 2001, one Australian citizen (aged 56
years) became ill after receiving a 17D-204 yellow fever vacci-
nation (34), and in 1999 and 2000, two Brazilian citizens
(aged 5 and 22 years) became ill 3–4 days after receiving 17DD
vaccine (35). Strain 17DD is different from strain 17D-204,
which is used in both the United States and Australia, but the
two viruses are derived from a common ancestor (17D virus)
and are closely related (13). In the Brazilian and Australian
cases, histopathologic changes in the liver included midzonal
necrosis, microvesicular fatty change, and Councilman bod-
ies, which are characteristic of wild-type yellow fever. Yellow
fever antigen was identified by IHC in areas of midzonal
necrosis in liver specimens from the two 17DD recipients,
and flavivirus-like particles consistent with yellow fever virus
were identified by electron microscopy in areas of midzonal
necrosis in a liver specimen from the 17D-204 recipient. Yel-
low fever vaccine virus (17DD or 17D-204) was isolated from
blood and autopsy material (i.e., brain, liver, kidney, spleen,
lung, skeletal muscle, or skin) from each of these three per-
sons, all of whom died 8–11 days after vaccination.
In Brazil, an estimated 23 million vaccine doses were dis-
tributed in vaccination campaigns during the 15-month
period in which the two reported cases occurred 6 months
apart (42). Thus, a crude estimate of occurrence for this
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serious adverse event in Brazil might be 0.09/1,000,000 doses
distributed. However, certain limitations to this estimate
exist. First, the number of doses administered during a vacci-
nation campaign substantially overestimates the true number
of persons vaccinated since certain persons receive multiple
vaccinations. Second, experience in Brazil indicates that
approximately half of vaccinees are already immune to yellow
fever and thus, theoretically, would not be at risk for this
adverse event. And finally, the numerator is only derived from
published case studies, not from formal surveillance systems
and therefore probably underestimates the true number of cases
of this adverse event.
Because mutational changes associated with a reversion to
virulence were not detected in the genomes of 17DD vaccine
viruses recovered from patients and because these viruses had
a vaccine-type phenotype among experimental animals, Bra-
zilian authorities assume that the occurrences are caused by
undefined host factors (43).
Additional Case Reports. Three additional cases of severe
adverse events after yellow fever vaccination have been reported
in the scientific literature (37–39). These cases occurred among
persons aged 45, 50, and 71 years, and the patients required
hospitalization for illness, which was characterized by fever
and elevated liver enzymes (37–39) and renal abnormalities
(37,38). All three persons recovered from their illness. Yellow
fever virus was isolated from the blood of the one person tested
(38). Vaccine strain viremia after primary vaccination with
yellow fever vaccine frequently occurs among healthy persons,
but is usually waning or absent after the first week (2,30). Two
persons were tested for antibodies to yellow fever virus; one of
these patients had unusually high levels of yellow fever anti-
bodies (39), and the antibody levels of the other person were
described as having increased during the 3 days after adminis-
tration (38).
Summary of Case Reports. In the cases from Brazil and
Australia, a causal association between yellow fever vaccine-
associated viscerotropic disease and vaccination with 17DD
or 17D-204 yellow fever vaccine is supported by histopatho-
logic studies, isolation of genetically stable vaccine-type virus
from multiple tissues other than blood, and the temporal rela-
tionship between vaccination and illness onset. Thus, both
the 17DD and 17D-204 yellow fever vaccines must be con-
sidered as a possible, but rare, cause of yellow fever vaccine-
associated viscerotropic disease that is similar to fulminant
yellow fever caused by wild-type yellow fever virus. Accurately
measuring the incidence of this rare vaccine-associated vis-
cerotropic disease is impossible because adequate prospective
data are unavailable; however, crude estimates of the reported
frequency range from 0.09 (in Brazil) to 2.5 (in the United
States) per 1,000,000 doses distributed. The real incidence
might be higher (41).
Because of a lack of tissue specimens from the majority of
the U.S. cases of yellow fever vaccine-associated viscerotropic
disease, no definitive laboratory support for a causal relation-
ship exists for these cases. However, the recent receipt of yel-
low fever vaccination and the similarity of the clinical
symptoms among all four U.S. cases indicate that yellow fever
vaccine is a probable cause of the disease in these cases. Whether
and in what way underlying host factors (genetic or acquired)
or preexisting clinical conditions might have contributed to
the course or outcome of yellow fever vaccine-associated vis-
cerotropic disease is unknown.
Because of recent reports of yellow fever deaths among
unvaccinated travelers to areas endemic for yellow fever and
of these reports of vaccine-associated viscerotropic disease, phy-
sicians should be careful to administer yellow fever vaccine
only to persons truly at risk for exposure to yellow fever. Addi-
tional surveillance to better monitor and quantify yellow
fever vaccine-specific adverse outcomes should also be estab-
lished. Studies are being conducted to clarify the cause and
risk factors for these rare adverse events associated with the
17D yellow fever vaccines.
Precautions and Contraindications
Age
Infants aged <6 months are likely to be more susceptible to
the serious adverse reaction of yellow fever vaccine-associated
neurotropic disease (also known as postvaccinal encephalitis)
than older children, and vaccination of infants aged <6 months
is contraindicated. The risk for this complication appears age-
related. The manufacturer and FDA recommend that vacci-
nation of infants aged <9 months be avoided because of the
risk for encephalitis, and that travel of such persons to coun-
tries in yellow fever-endemic zones or to countries experienc-
ing an epidemic should be postponed or avoided, whenever
possible. In unusual circumstances, physicians considering
vaccinating infants aged <9 months who are traveling to
endemic areas should contact the Division of Vector-Borne
Infectious Diseases (telephone: 970-221-6400) or the Divi-
sion of Global Migration and Quarantine (telephone: 404-
498-1600) at CDC for advice.
A recent analysis of adverse events passively reported to
VAERS during 1990–1998 indicates that persons aged >65
years might be at increased risk for systemic adverse events
after vaccination, compared with younger persons (40). Trav-
elers aged >65 years should discuss with their physicians the
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risks and benefits of vaccination in the context of their
destination-specific risk for exposure to yellow fever virus. Nev-
ertheless, yellow fever remains a key cause of illness and death
in South America and sub-Saharan Africa where potential yel-
low fever transmission zones have expanded to urban areas
with substantial populations of susceptible humans and the
Ae. aegypti vector mosquito. In addition, unvaccinated U.S.
travelers to South America have contracted fatal yellow fever
(3,14–18). Consequently, despite these rare adverse events,
yellow fever vaccination of travelers to high-risk areas should
be encouraged as a key prevention strategy.
Pregnancy
The safety of yellow fever vaccination during pregnancy has
not been established, and the vaccine should be administered
only if travel to an endemic area is unavoidable and if an
increased risk for exposure exists. On the basis of clinical evalu-
ation of a total of 81 infants in two different studies who were
born to mothers vaccinated during pregnancy, infection of
the fetus with YF17D apparently occurs at a low rate (i.e., 1 of
81) and has not been associated with congenital anomalies
(2,44,45). In a recent case-control study of women vaccinated
with YF 17D during early pregnancy, the relative risk for spon-
taneous abortion was 2.3, but the difference was not statisti-
cally significant (95% confidence interval = 0.65–8.03) (46).
Information from limited clinical trials in Africa and Europe
indicates that the risk from vaccination for pregnant women
who cannot avoid mosquito exposure in yellow fever-endemic
areas is outweighed by the risk for yellow fever infection (44).
If international travel requirements are the only reason to vac-
cinate a pregnant woman, rather than an increased risk for
infection, efforts should be made to obtain a waiver letter from
the traveler’s physician (Appendix). Pregnant women who must
travel to areas where the risk for yellow fever infection is high
should be vaccinated and, despite the apparent safety of this
vaccine, infants born to these women should be monitored
closely for evidence of congenital infection and other possible
adverse effects resulting from yellow fever vaccination. If vac-
cination of a pregnant woman is deemed necessary, serologic
testing to document an immune response to the vaccine can
be considered, because the seroconversion rate for pregnant
women in a developing nation has been reported to be sub-
stantially lower than that observed for other healthy adults
and children (45). To discuss the need for serologic testing,
the appropriate state health department or the Division of
Vector-Borne Infectious Diseases (telephone: 970-221-6400)
or the Division of Global Migration and Quarantine (tele-
phone: 404-498-1600) at CDC should be contacted.
Nursing Mothers
Whether this vaccine is excreted in human milk is unknown.
No reports exist of adverse events or transmission of the 17D
vaccine viruses from nursing mother to infant. However, as a
precautionary measure, vaccination of nursing mothers should
be avoided because of the theoretical risk for the transmission
of 17D virus to the breast-fed infant. When travel of nursing
mothers to high-risk yellow fever-endemic areas cannot be
avoided or postponed, such persons can be vaccinated.
Altered Immune Status
Infection with yellow fever vaccine virus poses a theoretical
risk for encephalitis to 1) patients with acquired immunodefi-
ciency syndrome (AIDS); 2) patients who are infected with
HIV and have other manifestations of HIV infection (32); 3)
patients with leukemia, lymphoma, generalized malignancy;
or 4) those whose immunologic responses are suppressed by
corticosteroids, alkylating drugs, antimetabolites, or radiation.
Such patients should not be vaccinated. If travel to a yellow
fever-infected zone is necessary, patients should be advised of
the risks posed by such travel, instructed in methods for avoid-
ing vector mosquitoes, and supplied with vaccination waiver
letters by their physicians (Appendix). Low-dose (i.e., 20-mg
prednisone or equivalent/day), short-term (i.e., <2 weeks) sys-
temic corticosteroid therapy or intra-articular, bursal, or ten-
don injections with corticosteroids should not be sufficiently
immunosuppressive to constitute an increased hazard to
recipients of yellow fever vaccine.
Persons who are HIV-infected but do not have AIDS or
other symptomatic manifestations of HIV infection, who have
established laboratory verification of adequate immune sys-
tem function, and who cannot avoid potential exposure to
yellow fever virus should be offered the choice of vaccination.
Despite the theoretical risk for neuroinvasion and encephali-
tis, clinical or epidemiologic studies to evaluate the risk for
yellow fever vaccination among such recipients have not been
reported. If international travel requirements are the only rea-
son to vaccinate an asymptomatic HIV-infected person, rather
than an increased risk for infection, efforts should be made to
obtain a waiver letter from the traveler’s physician (Appen-
dix). Asymptomatic HIV-infected persons who must travel to
areas where the risk for yellow fever infection is high should
be offered the choice of vaccination and monitored closely for
possible adverse effects.
Data regarding seroconversion rates after yellow fever vacci-
nation among asymptomatic HIV-infected persons are lim-
ited, but they do indicate that the seroconversion rates among
such persons is reduced. One month after receiving a 17D
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yellow fever vaccination, only 70% of 33 HIV-infected adults
with CD4+ T lymphocyte cell counts >200/mm3 developed
neutralizing antibody (47). Yellow fever vaccine typically
induces seroconversion among >90% of healthy adults. Among
HIV-infected infants simultaneously vaccinated with a 17D
yellow fever and measles vaccines, only 3 of 18 developed neu-
tralizing antibody, compared with 74% of 57 HIV-seronegative
infants who simultaneously received the two vaccines (48).
Because vaccination of asymptomatic HIV-infected persons
might be less effective than that for persons not infected with
HIV, measurement of their neutralizing antibody response to
vaccination should be considered before travel. To discuss the
need for serologic testing, the appropriate state health depart-
ment or the Division of Vector-Borne Infectious Diseases (tele-
phone: 970-221-6400) or the Division of Global Migration
and Quarantine (telephone: 404-498-1600) at CDC should
be contacted. Family members of immunosuppressed or HIV-
infected persons, who themselves have no contraindications,
can receive yellow fever vaccine.
Hypersensitivity
Yellow fever vaccine is produced in chick embryos and should
not be administered to persons hypersensitive to eggs; typi-
cally, persons who are able to eat eggs or egg products can
receive the vaccine. If international travel regulations are the
only reason to vaccinate a patient hypersensitive to eggs,
efforts should be made to obtain a waiver (Appendix). If vac-
cination of a person with a questionable history of egg hyper-
sensitivity is considered essential because of a high risk for
exposure, an intradermal test dose can be administered under
close medical supervision. Specific directions for skin testing
are located in the package insert (49).
Simultaneous Administration
of Other Vaccines
Determination of whether to administer yellow fever vac-
cine and other immunobiologics simultaneously should be
made on the basis of convenience to the traveler in complet-
ing the desired vaccinations before travel and on information
regarding possible interference. The following discussion
should help guide these decisions.
Limited clinical studies have demonstrated that the sero-
logic response to yellow fever vaccine is not inhibited by the
administration of certain other vaccines concurrently or at
intervals of a 1 day–1 month (50). Measles, smallpox, and
yellow fever vaccines have been administered in combination
(51,52); Bacillus Calmette-Guérin (BCG) and yellow fever
vaccines have been administered simultaneously without
interference.
Yellow fever vaccine can be administered concurrently with
hepatitis A or hepatitis B vaccines (53, 54). In addition, yel-
low fever vaccine has been administered concurrently with the
typhoid fever vaccine, Typhim Vi® (manufactured by Aventis
Pasteur, Inc., Swiftwater, Pennsylvania) and the meningococ-
cal vaccine, Menomune® (Aventis Pasteur, Inc., Swiftwater,
Pennsylvania), with no reported evidence of an effect on the
immune response to any of the three vaccines individually
and no unusual safety problems (55). No data exist regarding
possible interference between yellow fever and rabies or Japa-
nese encephalitis vaccines.
In a prospective study of persons administered yellow fever
vaccine and an intramuscular dose of commercially available
immune globulin, no alteration of the immunologic response
to yellow fever vaccine was detected when compared with con-
trols (56). Although chloroquine inhibits replication of yel-
low fever virus in vitro, it does not adversely affect antibody




Yellow fever vaccine has been considered to be one of the
safest vaccines. The frequency of the adverse events reported
in these recommendations is low enough that, given the rela-
tively limited numbers of yellow fever vaccine doses adminis-
tered in the United States, sporadic cases of severe adverse events
that occurred earlier might not have been appreciated or
investigated. Unfortunately, yellow fever vaccine has been used
most widely during outbreaks and in areas where surveillance
for vaccine-associated adverse events has been difficult and
might have been masked by wild-type yellow fever infections.
The YF17D-associated adverse event reports, combined with
the growing momentum for mass vaccination in the wake of
increased yellow fever activity, underscore the importance of
further investigations to define and quantify YF17D vaccine
risks and to characterize their pathogenesis. Accordingly, the
following activities are recommended:
• Enhanced surveillance for systemic adverse events after
yellow fever vaccination should be introduced at U.S.-
certified yellow fever vaccination centers and in settings
where yellow fever vaccine is administered in other coun-
tries. The majority of yellow fever vaccine administered
in the United States is done through the vaccination of
U.S. military personnel and their dependents. The vac-
cine safety profile among U.S. military personnel might
not be representative of the U.S. population at large; how-
ever, this population might still serve as an excellent source
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of additional information in quantifying the risk for
adverse events through both retrospective and prospec-
tive studies. Accordingly, the U.S. military should be
encouraged to share information regarding its yellow
fever vaccination program, including annual number of
doses administered and substantial adverse events that
might be related to yellow fever vaccine.
• Although neurovirulence assays among primates were
required to qualify yellow fever vaccine in different pro-
duction stages, certain patients described in a recent
report exhibited viscerotropic (e.g., hepatic, renal, or car-
diac) abnormalities that might not have been detected
earlier. Viscerotropic safety tests consist of assays to mea-
sure viremia on days 2, 4, and 6 (2). Additional tests to
monitor hepatic, renal, and cardiac function and injury
should be considered.
• A protocol for the appropriate clinical, epidemiologic, and
laboratory evaluation of cases of viscerotropic or neuro-
tropic disease after yellow fever vaccine should be created.
This protocol should highlight the challenges in estab-
lishing causality and emphasize the importance of histo-
pathology, viral isolation, molecular analysis, and virulence
testing of samples from patient specimens and vaccine lots.
• Additional research is needed to identify host, as well as
vaccine-specific, risk factors associated with neurotropic
or viscerotropic disease after yellow fever vaccination.
• Additional research is also needed to better identify the
reasons why certain travelers to yellow fever-endemic
areas do not get yellow fever vaccinations. Related research
is needed to develop interventions to decrease the per-
centage of travelers who are not properly vaccinated.
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Appendix
Waiver Letters from Physicians
A physician’s letter stating the contraindication to vaccination has been acceptable to certain governments outside the United
States. Ideally, the letter should be written on letterhead stationary and bear the stamp used by health department and official
vaccination centers to validate the International Certificate of Vaccination. When planning to use a waiver letter, the traveler
should also obtain specific and authoritative advice from the embassy or consulate of the country or countries she or he plans to
visit. Waivers of requirements obtained from embassies or consulates should be documented by appropriate letters and retained
for presentation with the International Health Certificate.
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1. Where does yellow fever transmission occur in the world?
A. Asia.
B. Africa and South America.
C. Africa and Asia.
D. North America.
E. Throughout the world.






3. Which of the following is not true concerning yellow fever:
A. Two forms of yellow fever, urban and jungle, are clinically and
epidemiologically identical.
B. In recent years, reinfestations of the mosquito vector have occurred in
certain countries in Central and South America.
C. Jungle yellow fever can most effectively be prevented by vaccination of
human populations at risk for exposure.
D. No effective specific antiviral therapy for yellow fever has been
identified.
E. The fatality rate of severe yellow fever is approximately 20%.
4. Which of the following best describes the licensed yellow fever vaccine?





5. Which of the following is not true regarding use of yellow fever vaccine
before international travel?
A. The yellow fever vaccine must be administered at an approved yellow
fever vaccination center.
B. The manufacturer’s produced vaccine must meet World Health
Organization standards.
C. The yellow fever vaccine must be administered at a U.S. federal
institution.
D. Vaccinees should receive an International Certificate of Vaccination
that has been completed, signed, and validated with the official stamp
where the vaccine was administered.
E. Certain countries might require proof of vaccination for entry.
6. According to international health regulations, the yellow fever





E. the vaccinee’s lifetime.
Goal and Objectives
This MMWR provides recommendations regarding use of yellow fever vaccine. These recommendations were developed by CDC staff members and the Yellow Fever
Working Group of the Advisory Committee on Immunization Practices (ACIP). The goal of this report is to provide health-care professionals guidance regarding
administration of yellow fever vaccine. Upon completion of this educational activity, the reader should be able to 1) describe the epidemiology of yellow fever; 2)
describe the components, handling, usage, and documentation requirements of the licensed yellow fever vaccine; 3) list primary target groups for yellow fever
vaccination; and 4) recognize the known adverse reactions after administration of yellow fever vaccine.
To receive continuing education credit, please answer all of the following questions.
7. All of the following are true regarding yellow fever vaccine-associated
neurotropic disease, except:
A. It was previously known as postvaccinal encephalitis.
B. This syndrome was recognized with the early uses of yellow fever
vaccine in the 1940s and led to enhanced safety with development of
the seed lot system in 1945.
C. This is the most common adverse event associated with the yellow
fever vaccine.
D. The majority of these cases have occurred in children aged <4 months.
E. These cases can be fatal.
8. Which of the following groups can be vaccinated routinely without
special safety considerations?
A. Children aged <9 months.
B. Pregnant women.
C. Persons with compromised immune systems.
D. All of the above.
E. None of the above.
9. Which of the following is not true regarding yellow fever vaccine-
associated viscerotropic disease?
A. Since 1996, <50 cases have been reported in the scientific literature.
B. Persons at greatest risk for yellow fever vaccine-associated viscerotropic
disease are those who receive booster vaccines.
C. This syndrome was newly recognized in 1996.
D. The clinical spectrum of yellow fever vaccine-associated viscerotropic
disease ranges from moderate illness to multiple organ system failure
and death.
E. This is a rare form of adverse event associated with yellow fever vaccine;
reported frequency of occurrence is 1:400,000, on the basis of review
of the Vaccine Adverse Reporting System data of 1990–1998.
10.  Which of the following clinical features have been described as part of






F. All of the above.
11. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
12. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.









































































































































































































































































































































































































































































































































































































































































































































































































































13. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.








15. How much time did you spend reading this report and completing the
exam?
A. 1–1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5 hours.
D. More than 2.5 hours.
16. After reading this report, I am confident I can describe the guidance
regarding administration of yellow fever vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe the
epidemiology of yellow fever.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can describe the
components, handling, usage, and documentation requirements of the
licensed yellow fever vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. After reading this report, I am confident I can list primary target
groups for yellow fever vaccination.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can recognize the known
adverse reactions after administration of yellow fever vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–10
1. B; 2. C; 3. A; 4. A; 5. C; 6. C; 7. C; 8. E; 9. B; 10. F.
21. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. The figure is useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. How did you learn about this continuing education activity?
A. Internet.
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